





NEW TREATMENTS FOR NON-SMALL CELL LUNG CANCER

For more information, visit www.amsi.org.au

Clinical Trials Program Advances at NYU Langone Hospital—Long Island

The completion of NYU Langone Health's full-asset merger with NYU Winthrop Hospital (now called NYU Langone Hospital—Long Island) in August 2019 expanded Perlmutter Cancer Center's clinical trials program into Long Island.

Janice Mehnert, MD, who joined NYU Langone in July 2020 as a member of the faculty in the Department of Medicine and associate director for clinical research at Perlmutter Cancer Center, oversees the expansion of early-phase trial activity in collaboration with the cancer center's network sites in Brooklyn and Long Island, with the aim of further developing a strong culture of clinical and translational investigation that cuts across campuses.

"We have engaged our faculty partners at NYU Langone Hospital—Long Island to be part of the process and really have a seat at the table, from initiating clinical trials to helping us write study concepts," she says.

Across New York City and Long Island, Perlmutter Cancer Center network sites serve a large, diverse population of patients, each with different needs that are essential to the cancer center's mission, Dr. Mehnert says. A strategic initiative has been launched to identify the patient populations that are currently served at NYU Langone Hospital—Long Island and match clinical research offerings to those populations. Plans are also underway to establish an early phase clinical trials program that will collaborate closely with the early phase program at Perlmutter Cancer Center in Manhattan.

"A cancer diagnosis is stressful enough for people without adding the need to travel for care," Dr. Mehnert says. "A lot of high-quality care can be delivered without traveling. We are trying to identify the niches that can be met close to home and the niches that require travel to our main campus in Manhattan so we can better serve the population that our health system sees."

TESTING ANTIBODY-DRUG CONJUGATE IN WOMEN WITH METASTATIC BREAST CANCER

ADJUVANT STUDY TARGETS RESECTED MELANOMA



Blood Cancer Program Grows at Perlmutter Cancer Center

A number of appointments in key research areas and infrastructure expansion has cemented Perlmutter Cancer Center's position as a nexus for blood cancer research and care.

Targeting Lung Cancer at the

ABSENCE OF CIRCULAR

PANCREATIC TUMORS ACT AS



Nature • • • • •
• • • • •



